LearnGlossaryMarketStocksSuperinvestorsSign in

BLCO

Bausch + Lomb Corporation

Healthcare · $6.1B market cap

Verdict

We can't put a fair value on BLCO right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-3.4% a year✗
Sales growth5.0% a year✗
Free cash flow growth-24.3% a year✗
Return on invested capital1.3%✗

Follow BLCO

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

3 of the investors we track hold BLCO. In Q2 2026, 1 opened a position. Who we track

Carl Icahn

Icahn Capital Management · as of Q2 2026

$58.0M

3,500,000 shares

Howard Marks

Oaktree Capital Management · as of Q2 2026

$57.0M

3,441,042 shares

Daniel Loeb

Third Point · as of Q2 2026

$1.4M

85,000 shares

Moves in Q2 2026

New position: Daniel Loeb

About Bausch + Lomb Corporation

Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential…

Medical - Instruments & Supplies

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works